Breaking News Instant updates and real-time market news.

XBIT

XBiotech

$11.12

0.1 (0.91%)

09:06
11/12/19
11/12
09:06
11/12/19
09:06

XBiotech announces first patient enrolled in study evaluating bermekimab

XBiotech has enrolled the first patient in a randomized, double-blind, placebo-controlled Phase 2 clinical study to evaluate its IL-1a blocking antibody therapy in patients with moderate to severe Atopic Dermatitis. The study will assess weekly bermekimab therapy to reduce inflammatory skin lesions, itch, and pain in patients suffering from eczema. The study will compare three groups of patients over 16 weeks of treatment: a weekly dosing group, a biweekly dosing group, and a placebo group. Percentage of patients who achieve a 75% reduction in skin disease after 16 weeks of treatment will be the primary measure of response. The Eczema Area Severity Index scoring system will be used to assess severity of inflammatory skin lesions. Another crucial assessment will be patient itch, which is often severe and unrelenting in this disease. A numeric rating scale will be used to assess itch and pain at various timepoints ranging from 4-16 weeks. For more information on this study please visit www.clinicaltrials.gov. Bermekimab was previously tested in a clinical study of patients with moderate to severe AD. Those results were previously presented at the annual conferences of the American Academy of Dermatology and the European Academy of Dermatology and Venerology by renowned dermatologists Dr. Eric Simpson and Dr. Alice Gottlieb, respectively. The findings showed that after only 8 weeks of bermekimab therapy, 75% of patients had achieved 75% improvement in disease severity as assessed by EASI score. Bermekimab therapy was also associated with a dramatic reduction in itch and pain, with three fourths of patients achieving clinically significant reduction in itch, and 86% achieving clinically significant reduction in pain after only 8 weeks of treatment.

XBIT XBiotech
$11.12

0.1 (0.91%)

06/14/19
PIPR
06/14/19
INITIATION
Target $13
PIPR
Overweight
XBiotech initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro started XBiotech with an Overweight rating and $13 price target. Clinical activity for the company's lead asset bermekimab in two inflammatory skin diseases - hidradenitis suppurativa and atopic dermatitis - has been "very encouraging," Catanzaro tells investors in a research note. He believes these early data compare favorably to standard of care biologics Humira and Dupixent in each setting, respectively. The analyst expects XBiotech shares to appreciate as it advances bermekimab in both indications.

TODAY'S FREE FLY STORIES

12:30
12/06/19
12/06
12:30
12/06/19
12:30
General news
Treasury's $25 B 2-year FRN reopening stopped at 0.245% »

Treasury's $25 B…

PIR

Pier 1 Imports

$7.70

-0.27 (-3.39%)

12:22
12/06/19
12/06
12:22
12/06/19
12:22
Periodicals
Pier 1 hired Guggenheim amid concerns over debt, Debtwire reports »

Pier 1 Imports has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDLA

Medallia

$29.11

-0.68 (-2.28%)

12:19
12/06/19
12/06
12:19
12/06/19
12:19
Recommendations
Medallia analyst commentary  »

Oppenheimer says would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

PIR

Pier 1 Imports

$7.92

-0.05 (-0.63%)

12:19
12/06/19
12/06
12:19
12/06/19
12:19
Periodicals
Breaking Periodicals news story on Pier 1 Imports »

Pier 1 hired financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
12/06/19
12/06
12:17
12/06/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
12/06/19
12/06
12:16
12/06/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$60.70

1.195 (2.01%)

, XLRN

Acceleron

$48.58

-0.08 (-0.16%)

12:08
12/06/19
12/06
12:08
12/06/19
12:08
Hot Stocks
Bristol-Myers, Acceleron: FDA says Reblozyl will not be reviewed at ODAC meeting »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$60.70

1.195 (2.01%)

XLRN

Acceleron

$48.58

-0.08 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

  • 04

    Apr

MNTA

Momenta

$17.53

0.68 (4.04%)

12:04
12/06/19
12/06
12:04
12/06/19
12:04
Hot Stocks
Momenta granted orphan status for hemolytic anemia treatment »

The FDA granted Momenta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 16

    Dec

EA

Electronic Arts

$102.74

0.66 (0.65%)

, ATVI

Activision Blizzard

$55.08

0.09 (0.16%)

12:03
12/06/19
12/06
12:03
12/06/19
12:03
Conference/Events
Wedbush digital media analyst to hold an analyst/industry conference call »

Digital Media Analyst…

EA

Electronic Arts

$102.74

0.66 (0.65%)

ATVI

Activision Blizzard

$55.08

0.09 (0.16%)

GME

GameStop

$6.46

0.1 (1.57%)

NTDOY

Nintendo

$0.00

(0.00%)

TTWO

Take-Two

$123.21

-0.69 (-0.56%)

UBSFY

Ubisoft

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 13

    Dec

PRVL

Prevail Therapeutics

$14.02

-0.03 (-0.21%)

12:02
12/06/19
12/06
12:02
12/06/19
12:02
Hot Stocks
Prevail Therapeutics granted orphan status for dementia treatment »

The FDA granted Prevail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEI

Weidai

$4.10

-0.35 (-7.87%)

12:00
12/06/19
12/06
12:00
12/06/19
12:00
Hot Stocks
Weidai falls -8.3% »

Weidai is down -8.3%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PD

PagerDuty

$21.79

-3.2 (-12.81%)

12:00
12/06/19
12/06
12:00
12/06/19
12:00
Hot Stocks
PagerDuty falls -12.8% »

PagerDuty is down -12.8%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YEXT

Yext

$14.02

-2.595 (-15.62%)

12:00
12/06/19
12/06
12:00
12/06/19
12:00
Hot Stocks
Yext falls -15.4% »

Yext is down -15.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$17.08

2.02 (13.41%)

12:00
12/06/19
12/06
12:00
12/06/19
12:00
Hot Stocks
Chemours rises 13.4% »

Chemours is up 13.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

BIG

Big Lots

$24.21

5.04 (26.29%)

12:00
12/06/19
12/06
12:00
12/06/19
12:00
Hot Stocks
Big Lots rises 26.5% »

Big Lots is up 26.5%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

GCO

Genesco

$49.57

12.63 (34.19%)

12:00
12/06/19
12/06
12:00
12/06/19
12:00
Hot Stocks
Genesco rises 34.1% »

Genesco is up 34.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

UBER

Uber

$27.99

-0.655 (-2.29%)

, ALXN

Alexion

$112.31

4.89 (4.55%)

11:58
12/06/19
12/06
11:58
12/06/19
11:58
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks have been…

UBER

Uber

$27.99

-0.655 (-2.29%)

ALXN

Alexion

$112.31

4.89 (4.55%)

TTD

Trade Desk

$250.86

10.59 (4.41%)

BIG

Big Lots

$24.19

5.02 (26.19%)

ULTA

Ulta Beauty

$267.17

31.08 (13.16%)

CIEN

Ciena

$34.98

-1.32 (-3.64%)

PD

PagerDuty

$21.81

-3.18 (-12.73%)

YEXT

Yext

$13.99

-2.625 (-15.80%)

ZM

Zoom Video

$62.23

-7.5 (-10.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 16

    Dec

  • 16

    Dec

  • 12

    Mar

11:58
12/06/19
12/06
11:58
12/06/19
11:58
Conference/Events
Oppenheimer healthcare analysts to hold a KOL dinner meeting »

Analysts hold a Cardiac…

F

Ford

$9.06

0.13 (1.46%)

11:58
12/06/19
12/06
11:58
12/06/19
11:58
Hot Stocks
Ford issues two safety recalls in North America »

Ford Motor Company is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 07

    Jan

  • 04

    Feb

11:57
12/06/19
12/06
11:57
12/06/19
11:57
Conference/Events
William Blair insurance analyst to hold a luncheon meeting »

Insurance Analyst Adam…

11:55
12/06/19
12/06
11:55
12/06/19
11:55
Conference/Events
BTIG oil and tanker analysts to hold a roundtable »

Oil Flow & Tanker…

GS

Goldman Sachs

$223.33

6.1 (2.81%)

11:54
12/06/19
12/06
11:54
12/06/19
11:54
Periodicals
U.S. discussing Goldman Sachs settlement for 1MDB under $2B, Bloomberg says »

The DOJ and other federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

  • 26

    Feb

GGG

Graco

$49.25

0.84 (1.74%)

11:53
12/06/19
12/06
11:53
12/06/19
11:53
Hot Stocks
Graco raises quarterly dividend 9.4% to 17.5c per share »

Graco's board has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZGNX

Zogenix

$46.15

0.5 (1.10%)

11:44
12/06/19
12/06
11:44
12/06/19
11:44
Recommendations
Zogenix analyst commentary  »

2020 looking to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

ARD

Ardagh Group

$18.88

(0.00%)

, CCK

Crown Holdings

$76.07

0.26 (0.34%)

11:42
12/06/19
12/06
11:42
12/06/19
11:42
Recommendations
Ardagh Group, Crown Holdings, Ball Corp. analyst commentary  »

FCD can plant news…

ARD

Ardagh Group

$18.88

(0.00%)

CCK

Crown Holdings

$76.07

0.26 (0.34%)

BLL

Ball Corp.

$66.18

0.02 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.